Premium Reports
IV Compounding 2019

IV Compounding 2019
New Options Garner Consideration, But Traditional Solutions Still Outperform

Authored by: Paul Hess, Jackson Tate, and Paul Warburton March 21, 2019 | Read Time: 3  minutes

Current Time Inside Cache Tag Helper: 1/25/2021 5:42:20 AM and Model.reportId = 1465

While patient safety and regulatory compliance are the main purchasing drivers for IV workflow management solutions and IV robots, many organizations are also looking to consolidate their pharmacy systems. To this end, organizations are wondering whether the workflow management solutions from EMR vendor Epic and broader pharmacy vendors BD and Omnicell are performing on par with those of the strong traditional players Baxter and Grifols. IV robots continue to fall short of customers’ expectations, though vendor acquisitions and mergers have shifted the performance landscape. Against this market backdrop, this report examines vendor differentiation in the key areas of market energy, patient safety, product throughput, and functionality.

Healthcare Providers,
Want to see full details?

Not a Provider, contact us for pricing details.

Current Time Inside Cache Tag Helper: 1/25/2021 5:42:20 AM and Model.reportId = 1465

Key Findings

  1. Gravimetric Functionality Increases Interest in BD but Poses Challenges
  2. Traditional Players Baxter and Grifols Drive Better Efficiency and ROI
  3. Epic Functionality Improving but Not There Yet
  4. Weaker Relationships Lead to ARxIUM Decline
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.